PHAR — Pharming Group N.V.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1828316 ·
Last close
$12.06
Market Cap
$853.58M
52W High
$21.34
52W Low
$9.11
ADV30
14,397
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 117,557,000 102,193,000 27,591,000 22,428,000 496,637,000 189,560,000 205,398,000
Jun 2026 90,213,000 75,668,000 -111,000 1,638,000 467,984,000 158,281,000 197,494,000
Mar 2026 72,447,000 65,803,000 -5,288,000 -5,213,000 489,365,000 52,379,000 220,405,000
Dec 2025 106,500,000 85,400,000 2,000,000 5,300,000 499,963,000 145,305,000 222,861,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$35,372,000
Investing CF
$-85,167,000
Financing CF
$-11,025,000
CapEx
$-870,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-255,277,000
Inventory
$57,988,000
Receivables
$74,831,000
ST Investments
$0
EBIT TTM
$28,392,000
Pretax Income TTM
$34,330,000
Interest Exp TTM
$14,717,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$366,479,008
EBITDA
$32,879,000
Free Cash Flow
$37,686,124
Enterprise Value
$748,436,800
Total Cash
$158,280,992
Total Debt
$113,295,000
Shares Out
70,778,124
Trailing EPS
$0.14
Book Value
$3.82
ROE
3.6%
ROA
3.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 376,134,000 20,881,000 2,851,000 499,963,000 222,861,000 277,102,000 54,708,000
Dec 2024 297,200,000 -3,665,000 -11,841,000 399,985,000 178,924,000 221,061,000 -1,795,000
Dec 2023 245,316,000 -22,289,000 -10,548,000 462,854,000 244,073,000 218,781,000 -17,302,000
Dec 2022 205,622,000 9,860,000 13,674,000 425,797,000 221,159,000 204,638,000 22,458,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.31

Peers — same industry

TickerNameMarket CapLastDaily %
CRVS Corvus Pharmaceuticals, Inc. $857.87M $10.17 —
CTY CITY THERAPEUTICS, INC. $846.44M $17.50 —
ORIC Oric Pharmaceuticals, Inc. $829.22M $8.00 —
AKTS Aktis Oncology, Inc. $879.52M $16.31 —
SNDX Syndax Pharmaceuticals Inc $828.26M $9.20 —

News headlines (Yahoo Finance, 1h cache)

Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
2026-11-11 07:00 · Yahoo
MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
2026-11-06 06:00 · Yahoo
Pharming: 3 Key Takeaways for Long-Term Investors
2026-11-04 22:20 · Yahoo
Pharming Group (ENXTAM:PHARM) Stock Faces A Q3 Earnings Valuation Gap
2026-10-28 05:17 · Yahoo
Pharming (PHAR) Q3 2026 Earnings Call Transcript
2026-10-27 17:30 · Yahoo
Pharming Group Q3 Earnings Call Highlights
2026-10-27 15:05 · Yahoo
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
2026-10-27 06:00 · Yahoo
Pharming Group announces third quarter 2026 revenues above market expectations
2026-10-22 05:00 · Yahoo
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
2026-10-14 06:00 · Yahoo
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
2026-09-22 05:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.